835 related articles for article (PubMed ID: 26071857)
1. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.
Pieroni M; Wan B; Zuliani V; Franzblau SG; Costantino G; Rivara M
Eur J Med Chem; 2015 Jul; 100():44-9. PubMed ID: 26071857
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
[TBL] [Abstract][Full Text] [Related]
3. Linked pyridinyl-thiadiazoles: Design and synthesis as potential candidate for treatment of XDR and MDR tuberculosis.
Mahajan NS; Dhawale SC
Eur J Med Chem; 2015 Sep; 102():243-8. PubMed ID: 26280920
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the research of heterocyclic compounds as antitubercular agents.
Yan M; Ma S
ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656
[TBL] [Abstract][Full Text] [Related]
5. Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.
Onajole OK; Pieroni M; Tipparaju SK; Lun S; Stec J; Chen G; Gunosewoyo H; Guo H; Ammerman NC; Bishai WR; Kozikowski AP
J Med Chem; 2013 May; 56(10):4093-103. PubMed ID: 23611124
[TBL] [Abstract][Full Text] [Related]
6. Ring-substituted imidazoles as a new class of anti-tuberculosis agents.
Gupta P; Hameed S; Jain R
Eur J Med Chem; 2004 Sep; 39(9):805-14. PubMed ID: 15337293
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and antimycobacterial evaluation of novel adamantane and adamantanol analogues effective against drug-resistant tuberculosis.
Alsayed SSR; Lun S; Payne A; Bishai WR; Gunosewoyo H
Bioorg Chem; 2021 Jan; 106():104486. PubMed ID: 33276981
[TBL] [Abstract][Full Text] [Related]
8. Pyrido[1,2-a]benzimidazole-based agents active against tuberculosis (TB), multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB.
Pieroni M; Tipparaju SK; Lun S; Song Y; Sturm AW; Bishai WR; Kozikowski AP
ChemMedChem; 2011 Feb; 6(2):334-42. PubMed ID: 21259445
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, biological evaluation, and structure-activity relationships for 5-[(E)-2-arylethenyl]-3-isoxazolecarboxylic acid alkyl ester derivatives as valuable antitubercular chemotypes.
Pieroni M; Lilienkampf A; Wan B; Wang Y; Franzblau SG; Kozikowski AP
J Med Chem; 2009 Oct; 52(20):6287-96. PubMed ID: 19757815
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Multiple Linear Regressions and Neural Networks based QSAR models for the design of new antitubercular compounds.
Ventura C; Latino DA; Martins F
Eur J Med Chem; 2013; 70():831-45. PubMed ID: 24246731
[TBL] [Abstract][Full Text] [Related]
11. 2,4-Dialkyl-8,9,10,11-tetrahydrobenzo[g]pyrimido[4,5-c]isoquinoline-1,3,7,12(2H,4H)-tetraones as new leads against Mycobacterium tuberculosis.
Claes P; Cappoen D; Uythethofken C; Jacobs J; Mertens B; Mathys V; Verschaeve L; Huygen K; De Kimpe N
Eur J Med Chem; 2014 Apr; 77():409-21. PubMed ID: 24681334
[TBL] [Abstract][Full Text] [Related]
12. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
Poce G; Cocozza M; Consalvi S; Biava M
Eur J Med Chem; 2014 Oct; 86():335-51. PubMed ID: 25173852
[TBL] [Abstract][Full Text] [Related]
13. QSAR-driven design, synthesis and discovery of potent chalcone derivatives with antitubercular activity.
Gomes MN; Braga RC; Grzelak EM; Neves BJ; Muratov E; Ma R; Klein LL; Cho S; Oliveira GR; Franzblau SG; Andrade CH
Eur J Med Chem; 2017 Sep; 137():126-138. PubMed ID: 28582669
[TBL] [Abstract][Full Text] [Related]
14. Novel 1-(4-substituted benzylidene)-4-(1-(substituted methyl)-2,3-dioxoindolin-5-yl)semicarbazide derivatives for use against Mycobacterium tuberculosis H37Rv (ATCC 27294) and MDR-TB strain.
Raja S; Prakash CR
Arch Pharm Res; 2013 Apr; 36(4):411-22. PubMed ID: 23440582
[TBL] [Abstract][Full Text] [Related]
15. Nontoxic Metal-Cyclam Complexes, a New Class of Compounds with Potency against Drug-Resistant Mycobacterium tuberculosis.
Yu M; Nagalingam G; Ellis S; Martinez E; Sintchenko V; Spain M; Rutledge PJ; Todd MH; Triccas JA
J Med Chem; 2016 Jun; 59(12):5917-21. PubMed ID: 27214150
[TBL] [Abstract][Full Text] [Related]
16. Neuroleptic drugs in the treatment of tuberculosis: Minimal inhibitory concentrations of different phenothiazines against Mycobacterium tuberculosis.
Vesenbeckh S; Krieger D; Bettermann G; Schönfeld N; Bauer TT; Rüssmann H; Mauch H
Tuberculosis (Edinb); 2016 May; 98():27-9. PubMed ID: 27156615
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.
Lilienkampf A; Mao J; Wan B; Wang Y; Franzblau SG; Kozikowski AP
J Med Chem; 2009 Apr; 52(7):2109-18. PubMed ID: 19271749
[TBL] [Abstract][Full Text] [Related]
18. Conjugation of a 5-nitrofuran-2-oyl moiety to aminoalkylimidazoles produces non-toxic nitrofurans that are efficacious in vitro and in vivo against multidrug-resistant Mycobacterium tuberculosis.
Krasavin M; Lukin A; Vedekhina T; Manicheva O; Dogonadze M; Vinogradova T; Zabolotnykh N; Rogacheva E; Kraeva L; Yablonsky P
Eur J Med Chem; 2018 Sep; 157():1115-1126. PubMed ID: 30179748
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and bioactivity of antitubercular peptides and peptidomimetics: an update.
De Leon Rodriguez LM; Kaur H; Brimble MA
Org Biomol Chem; 2016 Jan; 14(4):1177-87. PubMed ID: 26645944
[TBL] [Abstract][Full Text] [Related]
20. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
